Abstract: Objective To explore the efficacy of daggligin combined with metformin in obese/overweight type 2 diabetes patients. Methods The clinical data of 70 obese/overweight type 2 diabetes patients hospitalized in Taizhou Hospital of Traditional Chinese and Western Medicine from December 2022 to December 2023 were retrospectively analyzed. According to different treatment methods , the patients were divided into two groups of 35 cases, and the observation group of 35 cases. The control group was treated with metformin, while the observation group was treated with dapagliflozin tablets and their blood glucose, body mass index (BMI), homocysteine (Hcy) levels, and blood lipid indicators (total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol) were measured. Results The observation group showed better blood glucose control than the control group (P<0.05). The BMI of the observation group patients after treatment was (23.02±0.12) kg/m², while that of the control group was (25.23±0.31) kg/m². The observation group had a lower BMI and the difference was statistically significant (t=8.451, P<0.001). The Hcy index of the observation group after treatment was (7.00±1.04) μmol/L, while that of the control group was (10.85±2.14) μmol/L. The observation group had a lower BMI and the difference was statistically significant (t=6.254, P<0.001). Conclusion Daggligin combined with metformin is an effective and stable method for the combined treatment of obesity/overweight type 2 diabetes.

Key words: dapagliflozin, metformin, obesity, overweight, type 2 diabetes